Latest Hotspot

Epsilogen Advances Phase Ib Study of MOv18 IgE in Treatment-Resistant Ovarian Cancer with Regulatory Approval

10 July 2024
3 min read

Epsilogen, a prominent global entity in the advancement of immunoglobulin E antibodies for cancer treatment, has today revealed that the UK Medicines and Healthcare products Regulatory Agency has granted approval for the Clinical Trial Application of the Phase Ib study of MOv18 IgE.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 应用程序

描述已自动生成

The Phase Ib clinical trial is scheduled to commence in late 2024 and aims to assess the effectiveness of MOv18 IgE in individuals with ovarian cancer that is resistant to platinum-based therapies. 

Dr. Tim Wilson, the CEO of Epsilogen, stated, "The approval of this CTA marks a significant achievement for Epsilogen and the ongoing development of MOv18 IgE. We are eager to advance MOv18 IgE into a Phase Ib efficacy trial this year, reaffirming the potential of IgE antibodies as a novel class of cancer therapy."

MOv18 IgE is an IgE antibody that targets the folate receptor alpha (FR alpha) antigen. FR alpha is expressed in various cancers, including ovarian, endometrial, lung, and triple-negative breast cancers. Epsilogen has already completed a Phase I study focused on the safety of MOv18 IgE in patients with platinum-resistant ovarian cancer (PROC).

The findings, published in Nature Communications, indicated that MOv18 IgE is safe and well-tolerated, with observed signs of anti-tumor activity. Earlier this year, Epsilogen and its partner Lonza announced the successful large-scale production of MOv18 IgE under Good Manufacturing Practice (GMP) conditions.

The Phase Ib study’s objective is to verify the safety and tolerability of MOv18 IgE and to demonstrate its efficacy in PROC. Post dose-escalation, an expansion cohort will be involved to make a preliminary evaluation of MOv18 IgE's anti-tumor activity at a chosen dose. Additionally, the study will assess disease progression delay and include several translational elements to further understand the role of MOv18 IgE in the patient population.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of July 9, 2024, there are 77 investigational drugs for the FOLR1 target, including 99 indications, 76 R&D institutions involved, with related clinical trials reaching 140 and as many as 6771 patents.

MOv18 IgE is a monoclonal antibody that targets FOLR1 and is being developed for the treatment of various therapeutic areas including neoplasms, endocrinology and metabolic disease, respiratory diseases, skin and musculoskeletal diseases, and urogenital diseases. MOv18 IgE represents a promising advancement in the field of biomedicine, particularly in the treatment of various types of cancer and other related therapeutic areas. As the drug progresses through clinical trials, further research and development will be necessary to determine its efficacy and safety for patients.

图形用户界面, 文本, 应用程序

描述已自动生成

Is Ansuvimab-zykl approved by the FDA?
Drug Insights
3 min read
Is Ansuvimab-zykl approved by the FDA?
10 July 2024
Ansuvimab-zykl (Ebanga) was approved by the US Food and Drug Administration (FDA) on December 21, 2020, for the treatment of Zaire ebolavirus infection in both adults and pediatric patients.
Read →
HEMGENIX® Gene Therapy Used on First Hemophilia B Patients in Europe by CSL Behring
Latest Hotspot
3 min read
HEMGENIX® Gene Therapy Used on First Hemophilia B Patients in Europe by CSL Behring
10 July 2024
CSL Behring Treats First Hemophilia B Patients in Europe with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy.
Read →
Is Margetuximab approved by the FDA?
Drug Insights
3 min read
Is Margetuximab approved by the FDA?
9 July 2024
Margetuximab was approved by the US Food and Drug Administration (FDA) on December 16, 2020, for the treatment of metastatic HER2-positive breast cancer in combination with chemotherapy.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Jul 9
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Jul 9
9 July 2024
Jul 9th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.